In patients with cardiovascular risk factors and those at risk of HF, BNP assessment related to combination therapy reduces the combined incidence of left ventricular systolic dysfunction, diastolic dysfunction, and HF (84). This evidence concerns the gene NPPB and hydrops fetalis.